Galera Therapeutics (Galera Therapeutics) Debt-to-Asset : 0.05 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Galera Therapeutics Debt-to-Asset?

Galera Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.13 Mil. Galera Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.12 Mil. Galera Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $26.14 Mil. Galera Therapeutics's debt to asset for the quarter that ended in Dec. 2023 was 0.05.

Galera Therapeutics Debt-to-Asset Historical Data

The historical data trend for Galera Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galera Therapeutics Debt-to-Asset Chart

Galera Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

0.05

Galera Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															-	-	0.03	0.03	0.05

Competitive Comparison of Galera Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Galera Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galera Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galera Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Galera Therapeutics's Debt-to-Asset falls into.

Galera Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Galera Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.133	+	1.117)	/	26.141
	=	0.05

Galera Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.133	+	1.117)	/	26.141
	=	0.05

Galera Therapeutics (NAS:GRTX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Galera Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Galera Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Galera Therapeutics (Galera Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galera Therapeutics Inc (NAS:GRTX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 134, Malvern, PA, USA, 19355

Website

https://www.galeratx.com

Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Its lead product candidate, GC4419, is a small molecule dismutase mimetic developed for the reduction of severe oral mucositis, or SOM.

Executives

Mark Bachleda	officer: Chief Commercial Officer	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BOULEVARD, #110, MALVERN PA 19355
Chris Degnan	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Mel Sorensen	director, officer: President and CEO	7 RAPPS RUN DRIVE, MALVERN PA 19355
Eugene P. Kennedy	officer: Chief Medical Officer	2503 SOUTH LOOP DRIVE, AMES IA 50010
Linda West	director	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Jennifer Evans Stacey	officer: See Remarks	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Jon T Holmlund	officer: Chief Medical Officer
Lawrence M Alleva	director	1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Novo Holdings A/s	10 percent owner, other: SEE REMARKS	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joel F. Sussman	officer: Chief Accounting Officer	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD. #110, MALVERN PA 19355
Novartis Bioventures Ltd	10 percent owner	C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
New Enterprise Associates 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Clarus Iv-a, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Blackstone Clarus Gp L.p.	10 percent owner	C/O THE BLACKSTONE GROUP INC., 345 PARK AVENUE, NEW YORK NY 10154
Sofinnova Venture Partners Ix, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025